AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma

NCT05985694 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Eosinophilic Asthma

Interventions

DRUG: AD17002
DRUG: Placebo

Sponsor

Advagene Biopharma Co. Ltd.

Collaborators

[object Object]